Truvestments Capital’s Adamas Pharmaceuticals ADMS Stock Holding History

Truvestments Capital’s Portfolio ADMS Stock Details ADMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-637	Closed	-$3K	–	679
2021 Q3	$3K	Hold	637	–	–	﹤0.01%	528
2021 Q2	$3K	Hold	637	–	–	﹤0.01%	537
2021 Q1	$3K	Buy	637 +455	+250%	+$2.38K	﹤0.01%	604
2020 Q4	$0	Buy	+182	New	+$779	﹤0.01%	623
2019 Q4	–	Sell	-313	Closed	-$2K	–	666
2019 Q3	$2K	Sell	313 -37	-11%	-$228	﹤0.01%	673
2019 Q2	$2K	Hold	350	–	–	﹤0.01%	695
2019 Q1	$2K	Buy	+350	New	+$3.15K	﹤0.01%	692
2018 Q3	$7K	Buy	+351	New	+$8.24K	﹤0.01%	712

Truvestments Capital's ADMS Position: Q4 2021 in Review

Truvestments Capital sold out of Adamas Pharmaceuticals (ADMS) in Q4 2021, closing a stake of 637 shares — an estimated $3K sold.

Truvestments Capital first reported a position in ADMS in Q3 2018 and held it in 8 quarters. The position peaked at $7K in Q3 2018. 0 funds tracked by Wall St. Rank hold ADMS as of Q4 2021.

Truvestments Capital reported no remaining Adamas Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
Truvestments Capital sold 637 Adamas Pharmaceuticals shares in Q4 2021, an estimated $3K.
Truvestments Capital first reported a position in Adamas Pharmaceuticals in Q3 2018 and held it in 8 quarters.
Truvestments Capital's Adamas Pharmaceuticals position peaked at $7K in Q3 2018.
0 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q4 2021.

Based on Truvestments Capital's 13F filing for Q4 2021, filed 14 Feb 2022.